



JULY 17, 2020 | Number 8

XENOTHERA NEWS

Official news bulletin for XAV-19



EDITORIAL

by **Odile DUVAUX, President of XENOTHERA**

So soon we are again masked in public places... Whatever our opinion on this decision, it reminds us that SARS-CoV-2 is still circulating, and that cases of COVID-19, more or less benign, remain identified everywhere in France. Not mentioning the rest of the world, the United States, Latin America, and undoubtedly so many other places where patients are possibly unknown. This virus deserves being specifically targeted, with dedicated weapons specially designed to beat it, this is our ambition at XENOTHERA. All over the world, therapeutic and vaccine initiatives are multiplying, and there are more and more clinical trials. XAV-19 will be the first European specific clinical treatment and one of the first in the world. Let us not forget that unity is our strength and that the involvement of many of us will allow to win the battle. Above all, there will be one loser, the virus, and the union of the winners.

MAIN FOCUS Update on XAV-19 news

The news of XAV-19 is the expected authorization from the ANSM, which should reach us within a few days. It is also the favorable opinion of the CPP, ethics committee defending the sake of. It's finally the recruitment of more than 25 French hospitals already volunteering to participate in the clinical trial. The trial is called POLYCOR, it is sponsored by the Nantes University Hospital and benefits from "collaborative" public funding, encouraging collaboration between private (XENOTHERA) and public (CHU and University of Nantes).



Traitement anti-Covid : le consortium POLYCOR constitué de XENOTHERA, du Centre Hospitalo-Universitaire et de l'Université de Nantes obtient un financement de l'Etat français de près de 8 millions d'euros





POLYCOR funding also covers the industrialization of the production of XAV-19 and other XENOTHERA products. Thus we have started the first steps towards accelerated production. Creation of a pharmaceutical farm capable of producing 10 to 30,000 treatments per month, setting up of large-scale production, identification of partners who will accompany us on this path, everything is underway and starts in an intense and enthusiastic atmosphere. First step, minimal, the launch on Wednesday July 15 of the second batch of XAV-19, planned for more than 100 patients, and which will be available at the end of August. We move forward, step by step ...

TESTIMONY

Support of XENOTHERA

This week, find the testimony of Bruno Jarrosson, Strategy Consultant. Born the same year as Nicolas Sarkozy, Steve Jobs or Bill Gates, he has an inspiring and varied career! In particular, he worked for eight years as an electronics engineer, nine years as project manager at the Progrès du management association, then as associate director at DMJ Consultants. He leads numerous strategy missions in SMEs and created his consultancy company Better Call Bruno. He is also the author or co-author of thirty books and two plays.

[Click on the image to hear his testimony:](#)





In the media...

(Click on the images to access the articles)



Find our latest press releases:

- [Anti-Covid treatment: the POLYCOR consortium set up by XENOTHERA, the University Hospital Center and the University of Nantes obtains funding from the French State of almost 8 million euros \(July 15, 2020\) \(in french\)](#)
- [XENOTHERA secures funding of more than 7 million euros for its anti-Covid treatment and the acceleration of its product portfolio \(15th June 2020\)](#)
- [The search for Covid-19 treatments: how can the antibodies developed by the French biotech XENOTHERA help? \(30th April 2020\) \(in french\)](#)
- [LFB signs agreement with biotech XENOTHERA \(15th April 2020\)](#)
- [XENOTHERA launches support campaign to finalise treatment for coronavirus infections, including Covid-19 \(31th March 2020\)](#)

ABOUT XENOTHERA:

XENOTHERA, created in 2014, is a Nantes-based biotech company which develops “humanized” polyclonal antibodies. Their technological platform is based on dual expertise in animal genetics and a mastery of immunology. The company has a complete portfolio of products, the first of which, LIS1, an immunosuppressant for transplants, has been in clinical trials since 2019. XENOTHERA is part of the Nantes scientific, medical and academic environment and is supported by the Pays de la Loire region’s Atlanpole competitiveness cluster. Since its creation, the company has raised 6 million euros in equity and has received support from the BPI.

For more information go to www.xenothera.com

Follow XENOTHERA on social media :



Contact :

XENOTHERA

1 rue Vauban - 44 000 Nantes

xenothera@izsogood.co